Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The effect of RVG-SCMH1-Evs treatment on photothrombotic (PT) stroke mice

ABSTRACT: Metabolic dysfunction is considered a key event after ischemic stroke. However, the underlying mechanisms of metabolic disorders in cerebral ischemia is unknown. Circular RNA SCMH1 (circSCMH1), a circular RNA that has been reported to function in brain repair after stroke, was confirmed to be involved in metabolic disorders. circSCMH1 was delivered by rabies virus glycoprotein (RVG)-modified sxtracellular vesicle. Mechanistically, circSCMH1 decreased kynurenine 3-monooxygenase (KMO) expression, a key enzyme in kynurenine metabolism. Our findings suggested that circSCMH1 inhibited KMO expression, providing insight into the mechanism by which circSCMH1 promotes stroke recovery.

ORGANISM(S): Mus musculus

PROVIDER: GSE261613 | GEO | 2024/05/26

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

RNAseq data on single dose KMO inhibitor (CHDI-00340246) treated R6/2 mice.

Project description:Dysregulation of the kynurenine (Kyn) pathway has been associated with the progression of Huntington's disease (HD). In particular, elevated levels of the kynurenine metabolites 3-hydroxy kynurenine (3-OH-Kyn) and quinolinic acid (Quin), have been reported in the brains of HD patients as well as in rodent models of HD. The production of these metabolites is controlled by the activity of kynurenine mono-oxygenase (KMO), a mitochondrial outer membrane enzyme which catalyzes the synthesis of 3-OH-Kyn from Kyn. Thus inhibiting KMO is expected to produce a beneficial effect in Huntington's Disease (HD) patients, hopefully reversing their phenotype to match healthy subjects. To test this effect, we acutely treated a mouse model of HD (R6/2, a transgenic mouse model of HD which contains a human HTT gene containing 90 CAG repeats) and wild type mice with a KMO inhibitor, and separately used a mock treatment on both the transgenic mice and wild type mice. The goal of this project is to analyze the RNA-seq data and find gene expression changes associated with the KMO inhibitor

2017-10-30 | GSE106161 | GEO

RNA-Seq data on KMO inhibitor (CHDI-00340246) subchronic treated R6/2 mice.

Project description:Dysregulation of the kynurenine (Kyn) pathway has been associated with the progression of Huntington's disease (HD). In particular, elevated levels of the kynurenine metabolites 3-hydroxy kynurenine (3-OH-Kyn) and quinolinic acid (Quin), have been reported in the brains of HD patients as well as in rodent models of HD. The production of these metabolites is controlled by the activity of kynurenine mono-oxygenase (KMO), a mitochondrial outer membrane enzyme which catalyzes the synthesis of 3-OH-Kyn from Kyn. Thus inhibiting KMO is expected to produce a beneficial effect in Huntington's Disease (HD) patients, hopefully reversing their phenotype to match healthy subjects. To test this effect, we chronically treated a mouse model of HD (R6/2, a transgenic mouse model of HD which contains a human HTT gene containing 90 CAG repeats) and wild type mice with a KMO inhibitor for 8 weeks, and separately used a mock treatment on both the transgenic mice and wild type mice. The goal of this project is to analyze the RNA-seq data and find gene expression changes associated with the KMO inhibitor.

2017-10-30 | GSE105158 | GEO

kmo

Project description:Xenopus tropicalis kmo, kynurenine 3-monooxygenase (kynurenine 3-hydroxylase) [Source:Xenbase;Acc:XB-GENE-966665], is expressed in 1 baseline experiment(s);

| ENSXETG00000016227 | ExpressionAtlas

Kmo

Project description:Mus musculus Kmo, kynurenine 3-monooxygenase (kynurenine 3-hydroxylase) [Source:MGI Symbol;Acc:MGI:2138151], is differentially expressed in 93 experiment(s);

| ENSMUSG00000039783 | ExpressionAtlas

Kmo

Project description:Mus musculus Kmo, kynurenine 3-monooxygenase (kynurenine 3-hydroxylase) [Source:MGI Symbol;Acc:MGI:2138151], is expressed in 20 baseline experiment(s);

| ENSMUSG00000039783 | ExpressionAtlas

kmo

Project description:Danio rerio kmo, kynurenine 3-monooxygenase [Source:NCBI gene;Acc:368242], is differentially expressed in 3 experiment(s);

| ENSDARG00000009160 | ExpressionAtlas

Kmo

Project description:Rattus norvegicus Kmo, kynurenine 3-monooxygenase [Source:RGD Symbol;Acc:620610], is differentially expressed in 19 experiment(s);

| ENSRNOG00000003709 | ExpressionAtlas

kmo

Project description:Danio rerio kmo, kynurenine 3-monooxygenase [Source:NCBI gene;Acc:368242], is expressed in 1 baseline experiment(s);

| ENSDARG00000009160 | ExpressionAtlas

Kmo

Project description:Rattus norvegicus Kmo, kynurenine 3-monooxygenase [Source:RGD Symbol;Acc:620610], is expressed in 5 baseline experiment(s);

| ENSRNOG00000003709 | ExpressionAtlas

KMO

Project description:Monodelphis domestica KMO, kynurenine 3-monooxygenase [Source:NCBI gene;Acc:100027721], is expressed in 2 baseline experiment(s);

| ENSMODG00000006989 | ExpressionAtlas

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data